Skip to main navigation Skip to search Skip to main content

Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia

    • AstraZeneca

    Project: Clinical Trial

    Project Details

    Description

    A Multicenter Retrospective Study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia A retrospective, multi-centre, observational study to describe disease characteristics, treatment patterns, treatment-related outcomes, and resource utilization for Chronic Lymphocytic Leukemia (CLL) patients in multiple international regions

    Layman's description

    CREEK is a retrospective, observational, registry-based study including patients with an incidental diagnosis of CLL and started treatment (1st line, 2nd line, or Subsequent lines of treatment) within the period between 01 June 2016 and 12 months before data collection as identified from the patient records (from participating hospitals across the GCC States and the International region countries) with at least 12 months of follow-up, after starting on treatment.

    Moreover, the study will include a pilot cohort in the GCC as an exploratory objective to describe the clinical and patient characteristics for the treatment-naive CLL patient
    AcronymCREEK
    StatusFinished
    Effective start/end date3/12/2131/08/23

    Collaborative partners

    Keywords

    • Chronic lymphocytic leukemia
    • CLL
    • Neoplasms by Histologic Type
    • Neoplasms
    • Hematologic Diseases
    • Lymphoproliferative Disorders
    • Lymphatic Diseases
    • Immunoproliferative Disorders
    • Immune System Diseases
    • Leukemia, B-Cell
    • Chronic Disease
    • Disease Attributes
    • Pathologic Processes
    • Leukemia
    • Leukemia, Lymphoid
    • Leukemia, Lymphocytic, Chronic, B-Cell

    Fingerprint

    Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.